Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 See also  





2 References  





3 Further reading  





4 External links  














Interferon alfa-2b






العربية
Català
Español

Português
Русский
Српски / srpski
Srpskohrvatski / српскохрватски
Українська
Tiếng Vit
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 




In other projects  



Wikimedia Commons
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 

(Redirected from Interferon alfa 2b)

Interferon alfa-2b
Clinical data
MedlinePlusa690006
License data
Routes of
administration
Subcutaneous, intramuscular
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
  • US: ℞-only
  • Identifiers
    IUPHAR/BPS
    DrugBank
    ChemSpider
    • none
    ChEMBL
    ECHA InfoCard100.208.165 Edit this at Wikidata
     ☒NcheckY (what is this?)  (verify)

    Interferon alfa-2b is an antiviral or antineoplastic drug. It is a recombinant form of the protein Interferon alpha-2 that was originally sequenced and produced recombinantly in E. coli[1] in the laboratory of Charles Weissmann at the University of Zurich, in 1980.[2][3] It was developed at Biogen, and ultimately marketed by Schering-Plough under the trade name Intron-A. It was also produced in 1986 in recombinant human form, in the Center for Genetic Engineering and Biotechnology of Havana, Cuba, under the name Heberon Alfa R.[4]

    It has been used for a wide range of indications, including viral infections and cancers. This drug is approved around the world for the treatment of chronic hepatitis C, chronic hepatitis B, hairy cell leukemia, Behçet's disease, chronic myelogenous leukemia, multiple myeloma, follicular lymphoma, carcinoid tumor, mastocytosis and malignant melanoma.[citation needed]

    The medication is being used in clinical trials to treat patients with SARS-CoV-2[5] and there are published results in the peer-reviewed scientific literature.[6]

    So far, two non-peer reviewed research articles have been published. One study at the University of Texas Medical Branch, Galveston, showed evidence of a direct anti-viral effect of Interferon alpha against novel Coronavirus in vitro. The study demonstrated around 10,000 fold reduction in the quantity of virus that was pre-treated with Interferon alpha 48 hours earlier. A second study by universities in China, Australia and Canada analysed 77 moderate COVID-19 subjects in Wuhan and observed that those who received Interferon alpha-2b showed a significant reduction in the duration of virus shedding period and even in levels of the inflammatory cytokine, IL-6. [7] [8]

    This drug is also used off-label in cats and dogs, both by injection and orally.[9] The cross-species nature of IFN-α allow it to work in non-human animals,[10] but the period of usefulness is limited by the production of antibodies against this foreign protein.[9]

    Interferon alfa-2b products[11]
    Product Manufacturer Features Special uses
    Alpharona Pharmaclon
    Intron-A/IntronA Schering-Plough
    Realderon Teva
    Reaferon EC GNC Vector
    Reaferon EC-Lipint Vector-Medica liposomal
    Infagel Vector-Medica ointment
    Recolin Vector-Medica
    Altevir Bioprocess subsidiary liquid, free of HSA
    Kipferon Alfarm combination with IgM, IgA, IgG
    Giaferon A/S Vitafarma
    Genferon Biocad
    Opthalamoferon Firn-M with dimedrol eye infections
    Heberon Alfa R BioCubaFarma, Cuban-Chinese joint venture ChangHeber[12][13] severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[14]

    See also

    [edit]

    References

    [edit]
    1. ^ Nagata S, Taira H, Hall A, Johnsrud L, Streuli M, Ecsödi J, et al. (March 1980). "Synthesis in E. coli of a polypeptide with human leukocyte interferon activity". Nature. 284 (5754): 316–320. Bibcode:1980Natur.284..316N. doi:10.1038/284316a0. PMID 6987533. S2CID 4310807.
  • ^ Weissmann C (2001). "Recombinant interferon - the 20th anniversary". In Buckel P (ed.). Recombinant Protein Drugs. Milestones in Drug Therapy. Basel: Birkhäuser. pp. 3–41. doi:10.1007/978-3-0348-8346-7_1. ISBN 978-3-0348-8346-7.
  • ^ Mantei N, Schwarzstein M, Streuli M, Panem S, Nagata S, Weissmann C (June 1980). "The nucleotide sequence of a cloned human leukocyte interferon cDNA". Gene. 10 (1): 1–10. doi:10.1016/0378-1119(80)90137-7. PMID 6157600.
  • ^ Nodarse-Cuní H, López-Saura PA (2017). "Cuban interferon alpha-2b. Thirty years as an effective and safe drug". Biotecnología Aplicada. 34 (1): 1211–1217. ISSN 1027-2852.
  • ^ O'Connor T (March 24, 2020). "Cuba uses "wonder drug" to fight coronavirus around the world despite U.S. sanctions". Newsweek.
  • ^ Pereda R, González D, Rivero HB, Rivero JC, Pérez A, Lopez LD, et al. (December 2020). "Therapeutic Effectiveness of Interferon Alpha 2b Treatment for COVID-19 Patient Recovery". Journal of Interferon & Cytokine Research. 40 (12): 578–588. doi:10.1089/jir.2020.0188. PMID 33337933. S2CID 229324680.
  • ^ "Zydus to test use of Hepatitis C medicine for virus". The Times of India. 21 April 2020.
  • ^ "BRIEF-Zydus Explores Biologicals Route to Treat Coronavirus with Interferon Alpha-2B". Reuters. 20 April 2020.
  • ^ a b Forney B. "Interferon Alpha-2B for Veterinary Use". Wedgewood Pharmacy. Archived from the original on 2021-10-19.
  • ^ Yang LM, Xue QH, Sun L, Zhu YP, Liu WJ (February 2007). "Cloning and characterization of a novel feline IFN-omega". Journal of Interferon & Cytokine Research. 27 (2): 119–127. doi:10.1089/jir.2006.0094. PMID 17316139.
  • ^ Bairamashvili DI, Rabinovich ML (2007). "Russia through the prism of the world biopharmaceutical market" (PDF). Biotechnol. J. 2 (7): 801–817. doi:10.1002/biot.200700091. PMID 17615600. S2CID 26770545. Archived from the original (PDF) on 2012-02-24. Retrieved 2009-06-14.
  • ^ Makichuk D (18 April 2020). "Covid contenders: Viral drugs that offer hope". Asia Times.
  • ^ "The famous Cuban interferon vs the SARS-CoV-2 coronavirus". 19 March 2020.
  • ^ "Medikament aus Kuba zur Behandlung des Coronavirus bald auch in Deutschland?". 30 March 2020.
  • Further reading

    [edit]
  • Nagata S, Taira H, Hall A, Johnsrud L, Streuli M, Ecsödi J, et al. (March 1980). "Synthesis in E. coli of a polypeptide with human leukocyte interferon activity". Nature. 284 (5754): 316–320. Bibcode:1980Natur.284..316N. doi:10.1038/284316a0. PMID 6987533. S2CID 4310807.
  • [edit]
  • t
  • e
  • t
  • e

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Interferon_alfa-2b&oldid=1190951605"

    Categories: 
    Antiviral drugs
    Drugs developed by Schering-Plough
    Drugs developed by Merck & Co.
    Antiinfective agent stubs
    Antineoplastic and immunomodulating drug stubs
    Hidden categories: 
    Articles with short description
    Short description matches Wikidata
    Articles with changed DrugBank identifier
    Chemicals that do not have a ChemSpider ID assigned
    Articles with changed EBI identifier
    ECHA InfoCard ID from Wikidata
    Infobox drug articles without a structure image
    Chemical articles without CAS registry number
    Articles without KEGG source
    Articles without InChI source
    Articles without UNII source
    Drug has EMA link
    Drugboxes which contain changes to verified fields
    All articles with unsourced statements
    Articles with unsourced statements from March 2020
    Commons category link from Wikidata
    All stub articles
     



    This page was last edited on 20 December 2023, at 20:09 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki